XoNovo

Small-molecule Drugs for Neurodegenerative Diseases

Health Tech & Life Sciences
Non Active, Sep 2019 ceased to operate
Seed , Israel Founded 2013
LinkedIn
Last updated 2026-06-18
Total raised
Last: 2015-01
Stage
Seed
Founded
2013
Headcount
30
HQ
, Israel
Sector
Health Tech & Life Sciences

About

XoNovo is a preclinical-stage biopharmaceutical company engaged in the development of small-molecule therapeutics for preventing the progressive loss of neuronal function across multiple neurodegenerative diseases. The company's short-term focus is on its lead drug, XN001, in support of filing an investigational new drug application for Batten disease (BD), also known as neuronal ceroid lipofuscinoses, a fatal neurodegenerative orphan disorder. XoNovo utilizes a novel approach of selective modulation of autophagy and axonal transport machinery in neurons. XN001 has been extensively tested in both in-vitro and in-vivo models, showing promising results in neurodegenerative diseases including BD, Alzheimer's disease, glioblastoma, muscular dystrophy, and tuberous sclerosis.

Funding history · 1 round · — total

2015-01
Undisclosed

Q&A

What is XoNovo's primary focus?
XoNovo is a preclinical-stage biopharmaceutical company focused on developing small-molecule therapeutics to prevent the progressive loss of neuronal function in neurodegenerative diseases. Their lead drug, XN001, is being developed for Batten disease (BD).
When was XoNovo founded?
XoNovo was founded in August 2013.
What is the current status of XoNovo?
XoNovo is currently inactive, having ceased operations in September 2019.
How many employees did XoNovo have?
XoNovo had an employee count in the 11-50 range.
Where is XoNovo headquartered?
XoNovo's headquarters are located in Ness Ziona, Israel.
Who are the co-founders of XoNovo?
The co-founders of XoNovo are Kenneth Hensley, Prof. and Rafi Gidron, Dr.
What is XoNovo's lead drug candidate?
XoNovo's lead drug candidate is XN001, which is being developed for Batten disease (BD).
What approach does XoNovo use in its drug development?
XoNovo utilizes a novel approach of selective modulation of autophagy and axonal transport machinery in neurons.

Team · 2

Founder · Co-founder
Founder · Co-founder
LinkedIn ↗

Sectors & technology

Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
BiologicalsCells
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business model
B2B

Tags

pharmaceuticalsalzheimers-diseasedrug-discoveryneurology
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)

External links

LinkedInlinkedin.com/company/10270585

Identifiers & details

Former namesFutuRx
Founded2013-8
Employees (exact)30
OfficesWilmington
Status reasonNon Active, Sep 2019 ceased to operate